CN205698707U - artificial pancreas - Google Patents
artificial pancreas Download PDFInfo
- Publication number
- CN205698707U CN205698707U CN201620151137.1U CN201620151137U CN205698707U CN 205698707 U CN205698707 U CN 205698707U CN 201620151137 U CN201620151137 U CN 201620151137U CN 205698707 U CN205698707 U CN 205698707U
- Authority
- CN
- China
- Prior art keywords
- glucose
- insulin
- value
- loop controller
- artificial pancreas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The open a kind of artificial pancreas of this utility model, including lasting blood glucose monitoring system, Intelligent closed-loop controller and intelligent injection pump, Intelligent closed-loop controller is connected with intelligent injection pump, continue blood glucose monitoring system and include glucose induction electrode, glucose sensor and blood sugar for human body value output module, glucose induction electrode is connected with glucose sensor, glucose sensor is connected with blood sugar for human body value output module, and blood sugar for human body value output module is connected with Intelligent closed-loop controller.Artificial pancreas of the present utility model can increase level according to blood sugar for human body, automatically gives intravenous insulin according to insulin titer set in advance, at regular intervals, again according to blood sugar level, adjusts the injection volume of insulin；If hypoglycemia occurs, then according to default quantitative relationship, a certain amount of 50% glucose injection of automatic intravenous injection, lasting hypoglycemia can be avoided the occurrence of；The operating procedure of artificial pancreas of the present utility model is simple, easy to use.
Description
Technical field
This utility model relates to a kind of medical apparatus and instruments, particularly relates to a kind of Intelligent adjustment insulin and glucose level
Artificial pancreas.
Background technology
Stress hyperglycemia refers to that during acute illness, emerging blood glucose raises phenomenon, i.e. blood glucose more than 7.8
Mmol/L and glycolated hemoglobin are less than 6.5%.The critical patient of intensive care unit(ICU) (ICU) is often accompanied by
Stress hyperglycemia and insulin resistant (IR), according to the literature, the generation of ICU patient's stress hyperglycemia
Rate about 43%-50%.Stress hyperglycemia can cause inflammation, immune dysfunction and the regulation of blood coagulation endothelial function
Obstacle, adds case fatality rate and the complication rate of ICU patient.
Use insulin by glycemic control within normal range, thus above-mentioned effect can have been reversed to a certain extent
Should, and then improve the prognosis of patient.At present, the regulation and control method of stress hyperglycemia has multiple, such as strengthening islets of langerhans
Extract for treating method, controlled variable injection of insulin method (SSI), subcutaneous injection of insulin method and computer auxiliary blood
Sugar control method etc., but all there is complex operation step, defect that operation easier is big.
Utility model content
For regulating and controlling the complex operation step that stress hyperglycemia method exists, the defect that operation easier is big at present,
This utility model provides a kind of artificial pancreas (or artificial pancreas).
Artificial pancreas described in the utility model, including insulin infusion pump, continues blood glucose monitoring system, intelligence
Closed loop controller, the described blood glucose monitoring system that continues includes glucose induction electrode, glucose sensor and monitoring
Value output module, wherein:
Described glucose induction electrode is connected with described glucose sensor, and described glucose sensor passes through described Fructus Vitis viniferae
Sugar induction electrode sensed current signal, and be converted to the signal of telecommunication；
Described glucose sensor is connected with described monitor value output module, and the signal of telecommunication is sent to the output of described monitor value
Module；
Described monitor value output module is connected with described Intelligent closed-loop controller, exports the signal of telecommunication to described Intelligent closed-loop
Controller；
Described Intelligent closed-loop controller operates described insulin infusion pump calibrated shot.
In a kind of preferred embodiment of the present utility model, described Intelligent closed-loop controller includes memory element, place
Reason device, input block, wherein, in described memory element, storage has insulin dosage value and the signal of telecommunication and parameter
Mapping relations, input block to Intelligent closed-loop controller input parameter, processor according to input parameter and
Monitor value output module exports inquires about reflect relevant to described parameter in the memory unit to the signal of telecommunication of processor
Penetrate relation, and calculate insulin dosage value；Described insulin infusion pump described processor control under according to meter
The insulin dosage value calculated is injected.
In a kind of preferred embodiment of the present utility model, described artificial pancreas also includes glucose injection pump, institute
State Intelligent closed-loop controller and operate described glucose injection pump calibrated shot.
In more preferred embodiment of the present utility model, in described memory element, storage has glucose volume value and electricity
Signal and the mapping relations of parameter, input block inputs parameter to Intelligent closed-loop controller, and processor is according to input
Parameter and monitor value output module export and inquire about in the memory unit and described ginseng to the signal of telecommunication of processor
The mapping relations that number is relevant, and calculate glucose volume value；Described glucose injection pump is in described processor control
Inject according to the glucose volume value calculated under system.
Wherein, in foregoing, described parameter can be include height, body weight, in the age any one or
Several, and the most described parameter at least includes height and body weight.
In a kind of more preferred embodiment, described memory element include the first memory module, the second memory module,
3rd memory module, the 4th memory module；Wherein,
Described first memory module for storing the first mapping relations of height, body weight and body surface area, a kind of height with
The combination of a body weight uniquely corresponding body surface area；
Described second memory module is used for the second mapping relations of memory bank surface area, blood glucose value and insulin dosage value,
A kind of body surface area insulin dosage value the most corresponding with the combination of blood glucose value；
Described 3rd memory module is used for storing fasting glucose, Fasting insulin and IRI (insulin resistance index)
And the 3rd mapping relations of ISI (insulin sensitivity index), a kind of fasting blood sugar and Fasting insulin
The unique corresponding IRI value of combination and ISI value；
Described 4th memory module is used for storing fasting glucose, Fasting insulin and FBCI (β cell function index)
The 4th mapping relations, the combination of an a kind of fasting blood sugar and Fasting insulin uniquely corresponding FBCI value.
In a kind of more preferred embodiment, described processor includes acquisition module, enquiry module and output module；
Wherein,
Described acquisition module receives the parameter of input equipment input；
Parameter and the signal of telecommunication of monitor value output module output that described enquiry module receives according to acquisition module are inquired about
And calculate insulin and/or glucose volume value；
Described output module to described insulin infusion pump and/or glucose injection pump export described insulin dosage value/or
Glucose.
In a kind of more preferred embodiment, described Intelligent closed-loop controller also includes display device, such as, is used for
IRI value, ISI value and the FBCI value that display inquiry obtains.
In more preferred embodiment of the present utility model, described Intelligent closed-loop controller can be to pass through wireless signal
And/or wire signal continues blood glucose monitoring system, described insulin infusion pump and/or glucose note with described respectively
Penetrate pump to connect.
In more preferred embodiment of the present utility model, described artificial pancreas may also include alarm device, described report
Alarm device with described Intelligent closed-loop controller and is preferably connected with described processor, and processor receives described
The signal of telecommunication also judges when detected value corresponding to this signal of telecommunication meets and/or do not meets predetermined threshold, and operation is reported to the police and filled
Put and report to the police.
Compared with prior art, this utility model has a following beneficial effect:
1, artificial pancreas of the present utility model can increase level, according to insulin set in advance according to blood sugar for human body
Titer gives intravenous insulin automatically, at regular intervals, again according to blood sugar level, adjusts insulin
Injection volume；If hypoglycemia occurs, then according to default quantitative relationship, automatic intravenous injection a certain amount of 50%
Glucose injection, can correct hypoglycemia；The operating procedure of artificial pancreas of the present utility model is simple, user
Just.
2, artificial pancreas of the present utility model is provided with alarm device, when obvious hypoglycemia or substantially hyperglycemia occur,
Artificial pancreas's influential point of viscera automatic alarm.
3, critical illness stress hyperglycemia can be carried out automatic, convenient and effectively adjust by artificial pancreas of the present utility model
Control.
Accompanying drawing explanation
Fig. 1 is the working method schematic diagram of artificial pancreas of the present utility model.
Detailed description of the invention
Below in conjunction with accompanying drawing, illustrate this utility model.In order to enable those skilled in the art to clear,
Intactly know content of the present utility model and the technical solution of the utility model can be implemented, disclosed in embodiment
Substantial amounts of details.But it is clear that ground, these details those skilled in the art is not had also to be able to implement this
The technical scheme of utility model, reaches the purpose of this utility model, it is achieved effect of the present utility model.These are thin
Joint is the optimum embodiment that inventor selects through substantial amounts of experiment, is not intended to limit this utility model
Protection domain.Protection domain of the present utility model is as the criterion with the content of claims, those skilled in the art
The technical scheme that member obtains without creative work according to present specification disclosure is also new in this practicality
In the protection domain of type.
Embodiment 1
Referring to Fig. 1, this utility model provides a kind of artificial pancreas, including lasting blood glucose monitoring system 13,
Intelligent closed-loop controller 1 and intelligent injection pump 10, described Intelligent closed-loop controller 1 and described intelligent injection pump
10 connect, and the described blood glucose monitoring system 13 that continues includes glucose induction electrode 14, glucose sensor 15
With blood sugar for human body value output module 16, described glucose induction electrode 14 is with described glucose sensor 15 even
Connecing, described glucose sensor 15 is connected with described blood sugar for human body value output module 16, described blood sugar for human body
Value output module 16 is connected with described Intelligent closed-loop controller 1.
Wherein, the described blood glucose monitoring system 13 that continues can blood sugar level to human body at set time intervals
Continue to monitor；Described Intelligent closed-loop controller 1 can receive what described lasting blood glucose monitoring system 13 recorded
Blood sugar for human body value.
Described blood glucose regulation program module 2 includes first memory module the 3, second memory module the 4, the 3rd storage
Module the 5, the 4th memory module 6, acquisition module 7, enquiry module 8 and output module 9.
Described first memory module 3 is for storing the first mapping relations of height, body weight and body surface area, a kind of
A height body surface area the most corresponding with the combination of body weight.
Described second memory module 4 maps with the second of insulin dosage value for memory bank surface area, blood glucose value
Relation, a kind of body surface area insulin dosage value the most corresponding with the combination of blood glucose value.
Described 3rd memory module 5 is used for storing fasting glucose, Fasting insulin and IRI (insulin resistant
Index) and the 3rd mapping relations of ISI (insulin sensitivity index), a kind of fasting blood sugar and fasting blood pancreas
The combination of island element uniquely corresponding IRI and ISI.
Described 4th memory module 6 is used for storing fasting glucose, Fasting insulin and FBCI (β cell merit
Can index) the 4th mapping relations, the combination of a kind of fasting blood sugar and Fasting insulin uniquely corresponding
FBCI。
Described acquisition module 7 is for obtaining the height of patient, body weight and the blood measured in real time according to the input of user
Sugar value, fasting blood sugar and Fasting insulin value.
Described enquiry module 8 reflects for described in the height obtained according to described acquisition module 7, weight query first
Penetrate relation, obtain unique corresponding body surface area, according to the described body surface area obtained and described acquisition module 7
The blood glucose value of the described real-time measurement obtained, inquires about described second mapping relations, obtains unique corresponding insulin
Volume value.The fasting glucose obtained according to described acquisition module 7 maps with Fasting insulin inquiry the described 3rd
Relation, obtains unique corresponding IRI and ISI.The fasting glucose obtained according to described acquisition module 7 and empty stomach
Blood insulin inquires about described 4th mapping relations, obtains unique corresponding FBCI.
Concrete inquiry mode is as follows:
Wherein, the unit of body surface area is m2, the unit of height is cm, and the unit of body weight is kg；
Insulin dosage value={ body surface area × 30 × 0.6 × 1000 × [(blood glucose value measured in real time
-0.1)/100]÷2}；
Wherein, the unit of insulin dosage value is U, and the unit of body surface area is m2, the blood glucose of measurement in real time
The unit of value is g/dl.According to insulin resistance index measured value, determine to use the insulin dosage calculating gained
100%, 2/3 or 1/3 or other ratio values of value.I.e. according to insulin resistance degree, determine insulin
Usage amount, insulin resistant is the most serious, uses insulin dosage value of calculation to titrate；Insulin resistant is medium,
The 2/3 of insulin dosage value of calculation is used to titrate；Insulin resistance degree is relatively low, uses insulin dosage
The 1/3 of value of calculation titrates.
Insulin resistance index (IRI)=(fasting blood sugar × Fasting insulin value)/22.5；
Wherein, the unit of described fasting blood sugar is mmol/L, and the unit of described Fasting insulin is
uU/ml；
Insulin sensitivity index (ISI)=1/ (fasting blood sugar × Fasting insulin value)；
Wherein, the unit of described fasting blood sugar is mmol/L, and the unit of described Fasting insulin is
uU/ml；
β cell function index (FBCI)=Fasting insulin value/fasting blood sugar；
Wherein, the unit of fasting blood sugar is mmol/L, and the unit of Fasting insulin is uU/ml；
During hypoglycemia (blood glucose < 3.9mmol/L), the computing formula of hypertonic glucose (50%GS) usage amount is such as
Under:
50%GS (glucose injection) usage amount (ml)=(3.9-blood glucose value) × 10 × 2.
Described output module 9 is for exporting, to described intelligent injection pump 10, the institute that described enquiry module 8 inquires
State insulin dosage value；Described enquiry module 8, after the insulin dosage value obtaining described unique correspondence, indicates
Described output module 9 exports the described insulin dosage value inquired.Described output module 9 exports and points out institute
State described IRI, ISI and FBCI value that output module 9 inquires.
Embodiment 2
On the basis of embodiment 1, described intelligent injection pump 10 also includes 50% Hypertonic glucose solution injection
Pump 12, described Intelligent closed-loop controller 1 respectively with described insulin infusion pump 11 and described 50% Gao Shen Portugal
Grape sugar juice syringe pump 12 connects.Described intelligent injection pump 10 is used for receiving described Intelligent closed-loop controller 1
The real-time insulin of output or the dosage of 50% Hypertonic glucose solution, and according to described dosage,
In certain time, patient is carried out infusion.
Described Intelligent closed-loop controller 1 continues blood sugar monitoring with described respectively by wireless signal or wire signal
System 13 and described intelligent injection pump 10 connect.
Artificial pancreas may also include alarm device, and described alarm device is connected with described Intelligent closed-loop controller 1.
By arranging alarm device, when obvious hypoglycemia or substantially hyperglycemia occur, artificial pancreas's influential point of viscera automatic alarm.
Embodiment 3
First described insulin infusion pump 11 and described 50% Hypertonic glucose solution syringe pump 12 are passed through vein
Infusion pipeline is connected to the intravenous of patient, the glucose induction electrode 14 of lasting blood glucose monitoring system 13
Implant in the subcutaneous tissue of patient, described Intelligent closed-loop controller 1 by wireless signal or wire signal respectively with
Described lasting blood glucose monitoring system 13, described insulin infusion pump 11 and described 50% Hypertonic glucose solution
Syringe pump 12 connects.
By lasting blood glucose monitoring system 13 at regular intervals (such as 3 minutes) to as described in Intelligent closed-loop control
Device 1 feeds back blood glucose value, and it is constant defeated that described Intelligent closed-loop controller 1 sets up insulin according to the body condition of patient
Enter amount, set blood glucose value L-H, when blood glucose value is less than L, stops input insulin, start described 50% high
Ooze injected glucose solutions pump 12 input glucose；When blood glucose value is higher than H, strengthen described insulin infusion pump
The output of 11, makes blood glucose value be maintained in the range of setting.When obvious hypoglycemia or obvious hyperglycemia occur
Time, described Intelligent closed-loop controller 1 sends signal to alarm device makes alarm device send alarm.
Therefore, artificial pancreas of the present utility model can increase level, according to set in advance according to blood sugar for human body
Insulin titer gives intravenous insulin automatically, at regular intervals, again according to blood sugar level, adjusts pancreas
The injection volume of island element；If there is hypoglycemia, then according to default quantitative relationship, automatic intravenous injection is a certain amount of
50% glucose injection, can avoid the occurrence of lasting hypoglycemia；The operating procedure of artificial pancreas of the present utility model
Simply, easy to use.Critical illness stress hyperglycemia can be carried out automatically, just by artificial pancreas of the present utility model
Prompt and effective regulation and control.
Above specific embodiment of the utility model is described in detail, but it has been only used as example, this practicality
Novel it is not restricted to particular embodiments described above.To those skilled in the art, any real to this
With the novel equivalent modifications carried out and substitute the most all among category of the present utility model.Therefore, without departing from this
The impartial conversion made under the spirit and scope of utility model and amendment, all should contain in scope of the present utility model
In.
Claims (9)
1. an artificial pancreas, it is characterised in that include insulin infusion pump, continue blood glucose monitoring system, Intelligent closed-loop controller, the described blood glucose monitoring system that continues includes glucose induction electrode, glucose sensor and monitor value output module, wherein:
Described glucose induction electrode is connected with described glucose sensor, and described glucose sensor is by described glucose induction electrode sensed current signal, and is converted to the signal of telecommunication；
Described glucose sensor is connected with described monitor value output module, and the signal of telecommunication is sent to described monitor value output module；
Described monitor value output module is connected with described Intelligent closed-loop controller, is exported by the signal of telecommunication to described Intelligent closed-loop controller；
Described Intelligent closed-loop controller operates described insulin infusion pump calibrated shot.
Artificial pancreas the most according to claim 1, it is characterised in that described artificial pancreas also includes glucose injection pump, described Intelligent closed-loop controller operates described glucose injection pump calibrated shot.
Artificial pancreas the most according to claim 1 and 2, it is characterized in that, described Intelligent closed-loop controller includes memory element, processor, input block, wherein, in described memory element, storage has insulin dosage value and the signal of telecommunication and the mapping relations of parameter, input block inputs parameter to Intelligent closed-loop controller, processor exports and inquires about the mapping relations relevant to described parameter according to parameter and the monitor value output module of input in the memory unit to the signal of telecommunication of processor, and calculates insulin dosage value；Described insulin infusion pump is injected according to the insulin dosage value calculated under described processor controls.
Artificial pancreas the most according to claim 3, it is characterized in that, in described memory element, storage has glucose volume value and the signal of telecommunication and the mapping relations of parameter, input block inputs parameter to Intelligent closed-loop controller, processor exports and inquires about the mapping relations relevant to described parameter according to parameter and the monitor value output module of input in the memory unit to the signal of telecommunication of processor, and calculates glucose volume value；Described glucose injection pump is injected according to the glucose volume value calculated under described processor controls.
Artificial pancreas the most according to claim 3, it is characterised in that described memory element includes the first memory module, the second memory module, the 3rd memory module, the 4th memory module；Wherein,
Described first memory module is for storing the first mapping relations of height, body weight and body surface area, a kind of height body surface area the most corresponding with the combination of body weight；
Described second memory module is for the second mapping relations of memory bank surface area, blood glucose value and insulin dosage value, a kind of body surface area insulin dosage value the most corresponding with the combination of blood glucose value；
Described 3rd memory module is used for storing fasting glucose, Fasting insulin and IRI (insulin resistance index) and the 3rd mapping relations of ISI (insulin sensitivity index), the combination of a kind of fasting blood sugar and Fasting insulin uniquely a corresponding IRI value and ISI value；
Described 4th memory module is used for storing fasting glucose, Fasting insulin and the 4th mapping relations of FBCI (β cell function index), the combination of an a kind of fasting blood sugar and Fasting insulin uniquely corresponding FBCI value.
Artificial pancreas the most according to claim 3, it is characterised in that described processor includes acquisition module, enquiry module and output module；Wherein,
Described acquisition module receives the parameter of input equipment input；
Insulin and/or glucose volume value are inquired about and calculated to parameter and the signal of telecommunication of monitor value output module output that described enquiry module receives according to acquisition module；
Described output module exports described insulin dosage value/or glucose to described insulin infusion pump and/or glucose injection pump.
Artificial pancreas the most according to claim 1, it is characterised in that described Intelligent closed-loop controller also includes display device.
Artificial pancreas the most according to claim 1 and 2, it is characterised in that described Intelligent closed-loop controller is connected with described blood glucose monitoring system, described insulin infusion pump and/or the glucose injection pump of continuing respectively by wireless signal and/or wire signal.
Artificial pancreas the most according to claim 3, it is characterized in that, described artificial pancreas also includes alarm device, described alarm device is connected with the processor of described Intelligent closed-loop controller, processor receives the described signal of telecommunication and judges when detected value corresponding to this signal of telecommunication meets and/or do not meets predetermined threshold, and operation alarm device is reported to the police.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620151137.1U CN205698707U (en) | 2016-02-29 | 2016-02-29 | artificial pancreas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620151137.1U CN205698707U (en) | 2016-02-29 | 2016-02-29 | artificial pancreas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205698707U true CN205698707U (en) | 2016-11-23 |
Family
ID=57334582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620151137.1U Expired - Fee Related CN205698707U (en) | 2016-02-29 | 2016-02-29 | artificial pancreas |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205698707U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106730153A (en) * | 2016-12-02 | 2017-05-31 | 杜少良 | A kind of modularization Regulation of blood glucose system |
| CN113030219A (en) * | 2021-05-24 | 2021-06-25 | 广州新诚生物科技有限公司 | Continuous glucose monitoring sensor and application thereof |
| CN116807464A (en) * | 2023-08-30 | 2023-09-29 | 武汉联影智融医疗科技有限公司 | Blood glucose control method and device based on artificial pancreas system and electronic equipment |
-
2016
- 2016-02-29 CN CN201620151137.1U patent/CN205698707U/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106730153A (en) * | 2016-12-02 | 2017-05-31 | 杜少良 | A kind of modularization Regulation of blood glucose system |
| CN106730153B (en) * | 2016-12-02 | 2019-10-01 | 杜少良 | A kind of modularization Regulation of blood glucose system |
| CN113030219A (en) * | 2021-05-24 | 2021-06-25 | 广州新诚生物科技有限公司 | Continuous glucose monitoring sensor and application thereof |
| CN116807464A (en) * | 2023-08-30 | 2023-09-29 | 武汉联影智融医疗科技有限公司 | Blood glucose control method and device based on artificial pancreas system and electronic equipment |
| CN116807464B (en) * | 2023-08-30 | 2024-01-26 | 武汉联影智融医疗科技有限公司 | Blood sugar control device based on artificial pancreas system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107715230B (en) | Insulin pump individuation configuration optimization system based on cloud big data | |
| JP3594897B2 (en) | Extrapolation system for glucose concentration | |
| AU2013280898B2 (en) | Method and system to handle manual boluses or meal events for closed-loop controllers | |
| US10188796B2 (en) | Method and system for management of diabetes with a glucose monitor and infusion pump to provide feedback on bolus dosing | |
| US8454576B2 (en) | Device and method for therapy calibration and safety response | |
| JP6239623B2 (en) | System and method for controlling an insulin infusion device | |
| CN205698707U (en) | artificial pancreas | |
| AU2018250241A1 (en) | Insulin-on-board accounting in an artificial pancreas system | |
| CN203749411U (en) | Closed-loop control injection pump device for electroencephalogram monitoring sedation depth | |
| US20130046281A1 (en) | Closed Loop Infusion Formulation Delivery System | |
| US20080269723A1 (en) | Closed loop/semi-closed loop therapy modification system | |
| CN105169525A (en) | Safeguarding techniques for a closed-loop insulin infusion system | |
| CN110289094B (en) | Expert rule-based insulin accurate administration decision method | |
| JP4806674B2 (en) | Continuous subcutaneous insulin infusion therapy | |
| WO2009060433A1 (en) | Assessing residual insulin time | |
| Khan et al. | Artificial pancreas coupled vital signs monitoring for improved patient safety | |
| CN213219990U (en) | Diabetes patient management system based on continuous monitoring of sweat and insulin infusion | |
| Doran | Modelling and control of hyperglycemia in critical care patients | |
| WO2024082651A1 (en) | Adaptive closed-loop control method based on linear model | |
| RU2778069C2 (en) | Accounting for residual amount of active insulin in artificial pancreas system | |
| Chee et al. | Automatic blood glucose level control using CGMS | |
| Alexandra et al. | Closed loop glucose control in critical care patients: Previous study for clinical essays | |
| Finan et al. | Pre-Filtering The Insulin Input Improves The Quality Of Empirical Models Identified From Clinical Type 1 Diabetes Data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161123 Termination date: 20180229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |